Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.
鈉葡萄糖共同轉運蛋白-2抑制劑在胰島素治療期間對1型糖尿病幼童是否安全?第一例帶有SLC5A2突變的1型糖尿病病例。
J Diabetes 2024-06-26
Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
SGLT2 抑制劑用於第一型糖尿病的荟萃分析:隨機對照試驗。
Prim Care Diabetes 2024-04-05
Safety and tolerability of sodium glucose cotransporter-2 inhibitors in children and young adults: A systematic review and meta-analysis.
兒童和年輕成人中鈉葡萄糖共同轉運蛋白-2抑制劑的安全性和耐受性:系統性回顧和荟萃分析。
Ann Pediatr Endocrinol Metab 2024-01-01
Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
SGLT-2 抑制劑在使用自動胰島素輸送系統的第一型糖尿病患者中的風險與益處 - 文獻回顧。
Int J Mol Sci 2024-03-08
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
成人先天性心臟病患者中鈉葡萄糖共轉運輸蛋白2抑制劑的效應。
J Am Coll Cardiol 2024-04-25
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.
二型糖尿病老年患者使用鈉-葡萄糖共轉運蛋白 2 抑制劑的益處與安全性。
Diabetes Metab J 2024-09-23
Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review.
SGLT2 抑制劑在治療成年型糖尿病 (MODY) 的療效與安全性:個案報告與文獻回顧。
Hormones (Athens) 2025-02-04